Adam Feuerstein

Elan Shares Rise on J&J Investment

By Adam Feuerstein

Elan announces a $1.5 billion investment by J&J wherein it will take over Elan's Alzheimer's unit and assume an 18.4% stake in the company.

Related Topics: Health Care | Drugs | Biotech

11:10AM 07/02/09

Biotech Stock Mailbag: Spectrum Pharmaceuticals

By Adam Feuerstein

Readers weigh in on Spectrum Pharma, Cell Therapeutics and Geron, and force us to explain -- again -- TheStreet's rules on stock ownership.

Related Topics: Health Care | Drugs | Biotech

09:42AM 07/02/09

AMAG's Got Room to Run

By Adam Feuerstein

Upside remains in AMAG stock price even with Feraheme approval.

Related Topics: Biotech | Health Care | Drugs

11:02AM 07/01/09

Acorda (RealMoney.com $)

By Adam Feuerstein

09:28AM 07/01/09

AMAG: Feraheme Approved (RealMoney.com $)

By Adam Feuerstein

04:54PM 06/30/09

Geron Fans Make Mountain Out of GE Molehill

By Adam Feuerstein

As with most announcements from Geron, investors overreact to news of a stem-cell deal with GE.

Related Topics: Biotech | Health Care | Drugs

12:41PM 06/30/09

AMAG: FDA Delays Feraheme Decision

By Adam Feuerstein

AMAG says it expects the FDA to make its approval decision on iron replacement therapy Feraheme within a few days.

Related Topics: Drugs | Biotech | Health Care

10:04AM 06/30/09

Biotech Calendar: Key Clinical Trial Dates

By Adam Feuerstein

Part 3 in our quick-and-dirty guide to upcoming clinical trial dates for drug and biotech companies.

Related Topics: Health Care | Biotech | Drugs

08:00AM 06/30/09

AMAG: FDA decision on Feraheme in a few days (RealMoney.com $)

By Adam Feuerstein

06:28AM 06/30/09

AMAG Awaiting FDA Approval of Feraheme (RealMoney.com $)

By Adam Feuerstein

11:43AM 06/29/09